Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling. - Zhu YY; Li AQ; Yang F; Dong YX; Huang YS; Meng XJ; Zhang DZ; Li Y; Xian YF; Zhu D; Feng M (Acta pharmacologica Sinica, 2026)